XML 88 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative and Licensing Arrangements - Funding Expenses (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Research and Development Arrangement, Contract to Perform for Others      
Research and development expense $ 1,953,295 $ 1,778,594 $ 1,640,508
Amgen, Inc      
Research and Development Arrangement, Contract to Perform for Others      
BeiGene’s portion of the development funding 148,391 108,608 195,357
Less: Amortization of research and development cost share liability 73,226 55,294 96,402
Research and development expense 75,165 $ 53,314 $ 98,955
Remaining portion of development funding cap $ 335,261